544P A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation

Abstract

HER2-directed therapies have improved clinical outcomes for solid cancer patients with HER2 overexpression. Despite this success, it still remains a challenge to cure the HER2 positive cancer patients with resistance to current HER2-directed therapy. Therefore, effective HER2-directed therapy needs to be developed for them, and one approach would be to combine with immunotherapy. 4-1BB (TNFSF9, CD137) is a member of the tumor necrosis factor receptor superfamily that functions as a potent co-stimulator to immune cells, especially on primed T and NK cells in tumors.